Does the media favor VERA or PROK?

In the previous week, Vera Therapeutics had 5 more articles in the media than ProKidney. MarketBeat recorded 9 mentions for Vera Therapeutics and 4 mentions for ProKidney. Vera Therapeutics' average media sentiment score of 0.67 beat ProKidney's score of 0.00 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, IMNM or PROK?

ProKidney has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunome $6.94M 303.20 -$212.39M -$2.38 N/A ProKidney $890K 610.91 -$68.99M -$0.53 N/A

Is IMNM or PROK more profitable?

Immunome has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% ProKidney -8,131.50% N/A -21.39%

Does the media favor IMNM or PROK?

In the previous week, Immunome and Immunome both had 4 articles in the media. Immunome's average media sentiment score of 0.05 beat ProKidney's score of 0.00 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PROK or ELVN?

In the previous week, ProKidney and ProKidney both had 4 articles in the media. ProKidney's average media sentiment score of 0.00 beat Enliven Therapeutics' score of -0.03 indicating that ProKidney is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enliven Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RARE or PROK?

In the previous week, Ultragenyx Pharmaceutical had 5 more articles in the media than ProKidney. MarketBeat recorded 9 mentions for Ultragenyx Pharmaceutical and 4 mentions for ProKidney. Ultragenyx Pharmaceutical's average media sentiment score of 0.29 beat ProKidney's score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KOD or PROK?

In the previous week, ProKidney had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 4 mentions for ProKidney and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.33 beat ProKidney's score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ProKidney (PROK) Competitors

$1.80 -0.05 (-2.70%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$1.77 -0.03 (-1.83%)

As of 06/5/2026 07:50 PM Eastern

Compare

PROK vs. VERA, IMNM, ELVN, RARE, and KOD

Should you buy ProKidney stock or one of its competitors? MarketBeat compares ProKidney with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProKidney include Vera Therapeutics (VERA), Immunome (IMNM), Enliven Therapeutics (ELVN), Ultragenyx Pharmaceutical (RARE), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.

How does ProKidney compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Vera Therapeutics presently has a consensus target price of $78.00, indicating a potential upside of 141.56%. ProKidney has a consensus target price of $7.40, indicating a potential upside of 311.11%. Given ProKidney's higher possible upside, analysts clearly believe ProKidney is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Vera Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

ProKidney has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
ProKidney	$890K	610.91	-$68.99M	-$0.53	N/A

In the previous week, Vera Therapeutics had 5 more articles in the media than ProKidney. MarketBeat recorded 9 mentions for Vera Therapeutics and 4 mentions for ProKidney. Vera Therapeutics' average media sentiment score of 0.67 beat ProKidney's score of 0.00 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vera Therapeutics has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
ProKidney	-8,131.50%	N/A	-21.39%

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Comparatively, 39.8% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

ProKidney beats Vera Therapeutics on 10 of the 16 factors compared between the two stocks.

How does ProKidney compare to Immunome?

Immunome (NASDAQ:IMNM) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Immunome has a beta of 2.04, indicating that its stock price is 104% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Immunome has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
ProKidney	-8,131.50%	N/A	-21.39%

ProKidney has lower revenue, but higher earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	303.20	-$212.39M	-$2.38	N/A
ProKidney	$890K	610.91	-$68.99M	-$0.53	N/A

44.6% of Immunome shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 7.2% of Immunome shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Immunome presently has a consensus target price of $33.17, indicating a potential upside of 78.51%. ProKidney has a consensus target price of $7.40, indicating a potential upside of 311.11%. Given ProKidney's higher probable upside, analysts plainly believe ProKidney is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Immunome and Immunome both had 4 articles in the media. Immunome's average media sentiment score of 0.05 beat ProKidney's score of 0.00 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProKidney beats Immunome on 10 of the 16 factors compared between the two stocks.

How does ProKidney compare to Enliven Therapeutics?

ProKidney (NASDAQ:PROK) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

51.6% of ProKidney shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 39.8% of ProKidney shares are held by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ProKidney has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

ProKidney has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	610.91	-$68.99M	-$0.53	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

In the previous week, ProKidney and ProKidney both had 4 articles in the media. ProKidney's average media sentiment score of 0.00 beat Enliven Therapeutics' score of -0.03 indicating that ProKidney is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enliven Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enliven Therapeutics has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
Enliven Therapeutics	N/A	-21.04%	-20.41%

ProKidney presently has a consensus price target of $7.40, indicating a potential upside of 311.11%. Enliven Therapeutics has a consensus price target of $61.80, indicating a potential upside of 78.05%. Given ProKidney's higher probable upside, research analysts plainly believe ProKidney is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

ProKidney beats Enliven Therapeutics on 9 of the 13 factors compared between the two stocks.

How does ProKidney compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
ProKidney	-8,131.50%	N/A	-21.39%

Ultragenyx Pharmaceutical presently has a consensus target price of $59.56, suggesting a potential upside of 171.85%. ProKidney has a consensus target price of $7.40, suggesting a potential upside of 311.11%. Given ProKidney's higher probable upside, analysts plainly believe ProKidney is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, ProKidney has a beta of 1.64, meaning that its stock price is 64% more volatile than the broader market.

ProKidney has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.21	-$575M	-$6.11	N/A
ProKidney	$890K	610.91	-$68.99M	-$0.53	N/A

In the previous week, Ultragenyx Pharmaceutical had 5 more articles in the media than ProKidney. MarketBeat recorded 9 mentions for Ultragenyx Pharmaceutical and 4 mentions for ProKidney. Ultragenyx Pharmaceutical's average media sentiment score of 0.29 beat ProKidney's score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ProKidney beats Ultragenyx Pharmaceutical on 9 of the 16 factors compared between the two stocks.

How does ProKidney compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

ProKidney has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
ProKidney	$890K	610.91	-$68.99M	-$0.53	N/A

In the previous week, ProKidney had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 4 mentions for ProKidney and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.33 beat ProKidney's score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProKidney	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kodiak Sciences has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, ProKidney has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Kodiak Sciences presently has a consensus target price of $42.14, suggesting a potential upside of 35.73%. ProKidney has a consensus target price of $7.40, suggesting a potential upside of 311.11%. Given ProKidney's higher possible upside, analysts clearly believe ProKidney is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 45.9% of Kodiak Sciences shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kodiak Sciences has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
ProKidney	-8,131.50%	N/A	-21.39%

Summary

ProKidney beats Kodiak Sciences on 9 of the 16 factors compared between the two stocks.

Get ProKidney News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROK vs. The Competition

Export

Metric	ProKidney	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$558.81M	$2.98B	$6.47B	$12.45B
Dividend Yield	N/A	1.70%	2.67%	5.34%
P/E Ratio	-3.40	17.86	23.69	23.63
Price / Sales	610.91	299.96	520.34	114.17
Price / Cash	N/A	56.21	42.35	57.17
Price / Book	-0.54	3.83	9.73	6.37
Net Income	-$68.99M	$75.85M	$3.56B	$337.36M
7 Day Performance	-1.64%	-1.79%	-2.92%	-2.38%
1 Month Performance	-8.16%	-7.61%	-0.85%	-0.57%
1 Year Performance	84.12%	14.99%	22.23%	25.53%

ProKidney Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROK ProKidney	1.5129 of 5 stars	$1.80 -2.7%	$7.40 +311.1%	+128.7%	$558.81M	$890K	N/A	3
VERA Vera Therapeutics	3.3128 of 5 stars	$31.27 +0.0%	$78.00 +149.4%	+5.4%	$2.24B	N/A	N/A	40	News Coverage Analyst Forecast
IMNM Immunome	3.7428 of 5 stars	$19.81 +2.4%	$33.17 +67.4%	+103.7%	$2.19B	$6.94M	N/A	40	News Coverage
ELVN Enliven Therapeutics	3.0183 of 5 stars	$36.03 +1.4%	$61.80 +71.5%	+62.4%	$2.16B	N/A	N/A	50	Analyst Forecast
RARE Ultragenyx Pharmaceutical	2.8014 of 5 stars	$22.41 +2.9%	$59.56 +165.8%	-40.6%	$2.15B	$673M	N/A	1,371	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROK) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProKidney (PROK) Competitors

PROK vs. VERA, IMNM, ELVN, RARE, and KOD

How does ProKidney compare to Vera Therapeutics?

Summary

How does ProKidney compare to Immunome?

Summary

How does ProKidney compare to Enliven Therapeutics?

Summary

How does ProKidney compare to Ultragenyx Pharmaceutical?

Summary

How does ProKidney compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProKidney (PROK) Competitors

PROK vs. VERA, IMNM, ELVN, RARE, and KOD

How does ProKidney compare to Vera Therapeutics?

Do analysts recommend VERA or PROK?

Which has more risk and volatility, VERA or PROK?

Which has better valuation & earnings, VERA or PROK?

Does the media favor VERA or PROK?

Is VERA or PROK more profitable?

Do institutionals & insiders believe in VERA or PROK?

Summary

How does ProKidney compare to Immunome?

Which has more volatility & risk, IMNM or PROK?

Is IMNM or PROK more profitable?

Which has better earnings and valuation, IMNM or PROK?

Do institutionals & insiders believe in IMNM or PROK?

Do analysts prefer IMNM or PROK?

Does the media favor IMNM or PROK?

Summary

How does ProKidney compare to Enliven Therapeutics?

Do insiders and institutionals believe in PROK or ELVN?

Which has more risk and volatility, PROK or ELVN?

Which has better earnings and valuation, PROK or ELVN?

Does the media prefer PROK or ELVN?

Is PROK or ELVN more profitable?

Do analysts rate PROK or ELVN?

Summary

How does ProKidney compare to Ultragenyx Pharmaceutical?

Do institutionals and insiders hold more shares of RARE or PROK?

Is RARE or PROK more profitable?

Do analysts recommend RARE or PROK?

Which has more risk & volatility, RARE or PROK?

Which has higher earnings and valuation, RARE or PROK?

Does the media favor RARE or PROK?

Summary

How does ProKidney compare to Kodiak Sciences?

Which has stronger valuation & earnings, KOD or PROK?

Does the media prefer KOD or PROK?

Which has more volatility & risk, KOD or PROK?

Do analysts rate KOD or PROK?

Do insiders & institutionals hold more shares of KOD or PROK?

Is KOD or PROK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROK vs. The Competition

ProKidney Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools